ANNX
$5.11-0.38 (-6.92%)
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 cl...
Recent News
Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4
Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for vonoprument (ANX007), an intravitreal therapy being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration. Company leaders and invited retinal expe
Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference
Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and CEO Douglas Love emphasizing upcoming clinical catalysts, ongoing regulatory work, and preparations f
Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX?
Earlier this month, Annexon submitted a Marketing Authorization Application to the European Medicines Agency for tanruprubart to treat Guillain-Barre syndrome, supported by randomized studies showing rapid effects on neuroinflammation and disability measures. The filing, alongside plans for a U.S. Biologics License Application and broader FORWARD study, positions tanruprubart as a potential first-in-class option in a disease with no FDA-approved treatments. We’ll now examine how Annexon’s...
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome
Annexon (ANNX) is back in focus after the company submitted a Marketing Authorization Application to the European Medicines Agency for tanruprubart in Guillain Barre syndrome, marking a key regulatory moment for this clinical program. See our latest analysis for Annexon. The MAA news arrives after a strong 90-day share price return of 92.09% and a 30-day share price return of 17.41%, pointing to building momentum despite a 1-day share price dip of 1.46% and mixed longer term total shareholder...
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead
Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of late-stage and mid-stage milestones that CEO Doug Love described as setting up 2026 as a “pivotal year” for the company. Love highlighted two registration-stage programs—ANX007 in geo